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Background:  Among patients with ischemic cardiomyopathy who have an indication for automated implantable cardioverter-defibrillator 
(AICD) the prevalence and long-term implications of a chronic coronary total occlusion (CTO) are not well defined. We hypothesized that 
CTOs are common and predictive of increased risk of arrhythmic events.
methods:  We included 116 patients who underwent coronary angiography and AICD implantation for primary and secondary prevention 
of sudden cardiac death at the Minneapolis VA Medical Center from 2000 to 2010. A chronic coronary total occlusion was defined as the 
presence of TIMI 0 (Thrombolysis in Myocardial Infarction) flow within the occluded segment with an estimated or known occlusion duration 
of >3 months. Primary end-points were death and appropriate AICD therapy.
results:  The majority of patients (97%) were white males. The mean age was 63.5 ± 14.2 years old and 73 (63%) had diabetes mellitus. 
Fifty-two patients (44.4%) had a CTO on coronary angiography and 33% had a history of ventricular arrhythmias prior to AICD implantation. 
During a mean follow-up of 12 years, 10 patients (19.2%) with a CTO received an appropriate AICD therapy and 3 (5.8%) died. Among 
patients without a CTO, six (9.4%) received an appropriate AICD therapy and 3 (4.7%) died. Although event rates were numerically higher 
in patients with CTOs the differences were not statistically significant (estimated rate of death or appropriate AICD therapy (per 100) and 
95% confidence intervals 0.33 (95% CI: 0.18-0.60) for the CTO group and 0.28 (95% CI: 0.14-0.54) for the no CTO group (p= NS for all 
comparisons).
Conclusion:  Patients with CTOs undergoing AICD implantation receive twice the number of appropriate AICD shocks relative to patients 
without a CTO. It is uncertain whether CTO revascularization could improve these outcomes after AICD implantation, thus prospective 
study of this matter is necessary.
